Role of peroxisome proliferator-activated receptors in osteoarthritis (Review)

Huang,Gang; Jiang,Wei; Xie,Weiyong; Lu,Wei; Zhu,Weimin; Deng,Zhenhan

doi:10.3892/mmr.2020.11798

Role of peroxisome proliferator-activated receptors in osteoarthritis (Review)

Authors:
- Gang Huang
- Wei Jiang
- Weiyong Xie
- Wei Lu
- Weimin Zhu
- Zhenhan Deng
View Affiliations

Affiliations: Department of Sports Medicine, Orthopedic Hospital of Longgang, Shenzhen, Guangdong 518116, P.R. China, Bone and Joint Department, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University and The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518020, P.R. China, Department of Sports Medicine, Shenzhen Second People's Hospital/The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong 518035, P.R. China
Published online on: December 22, 2020 https://doi.org/10.3892/mmr.2020.11798
Article Number: 159

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoarthritis (OA) is the most common form of arthritis, for which treatment options are not always satisfactory, since complete cure for OA is not yet possible. A better understanding of OA pathogenesis is thus important. The peroxisome proliferator‑activated receptor (PPAR) plays a major regulatory role in lipid metabolism and energy homeostasis. This review article aimed to discuss the biological function of PPARs, and their role in regulating OA progression, as well as the therapeutic aspect of PPARs in OA. Studies indicate that PPARs regulate articular cartilage homeostasis through the modulation of various signaling pathways, and reduce the inflammatory responses in human OA cartilage. Furthermore, the deficiency of PPARs in the articular cartilage might be responsible for the acceleration of severe OA by increasing catabolic activity and suppression of chondroprotection. Therapeutic applications of PPAR‑agonists can thus reduce the development of cartilage lesions by inhibiting the synthesis of various catabolic and inflammatory factors involved in the pathogenesis of OA. PPARs are thus important proteins in OA regulation, which may have significant importance in OA therapeutics.

View Figures

View References

1	Cucchiarini M, de Girolamo L, Filardo G, Oliveira JM, Orth P, Pape D and Reboul P: Basic science of osteoarthritis. J Exp Orthop. 3:222016. View Article : Google Scholar : PubMed/NCBI
2	Hügle T and Geurts J: What drives osteoarthritis?-synovial versus subchondral bone pathology. Rheumatology (Oxford). 56:1461–1471. 2017.PubMed/NCBI
3	Nelson AE: Osteoarthritis year in review 2017: Clinical. Osteoarthritis Cartilage. 26:319–325. 2018. View Article : Google Scholar : PubMed/NCBI
4	Xia B, Di Chen, Zhang J, Hu S, Jin H and Tong P: Osteoarthritis pathogenesis: A review of molecular mechanisms. Calcif Tissue Int. 95:495–505. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton JL and Im HJ: Osteoarthritis: Toward a comprehensive understanding of pathological mechanism. Bone Res. 5:160442017. View Article : Google Scholar : PubMed/NCBI
6	Vargas Negrín F, Medina Abellán MD, Hermosa Hernán JC and de Felipe Medina R: Treatment of patients with osteoarthritis. Aten Primaria. 46 (Suppl 1):39–61. 2014.(In Spanish). View Article : Google Scholar : PubMed/NCBI
7	Sun MM, Beier F and Pest MA: Recent developments in emerging therapeutic targets of osteoarthritis. Curr Opin Rheumatol. 29:96–102. 2017. View Article : Google Scholar : PubMed/NCBI
8	Chevalier X, Eymard F and Richette P: Biologic agents in osteoarthritis: Hopes and disappointments. Nat Rev Rheumatol. 9:400–410. 2013. View Article : Google Scholar : PubMed/NCBI
9	Mobasheri A and Batt M: An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 59:333–339. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wu J, Liu W, Bemis A, Wang E, Qiu Y, Morris EA, Flannery CR and Yang Z: Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis Rheum. 56:3675–3684. 2007. View Article : Google Scholar : PubMed/NCBI
11	Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M and Pelletier JP: The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum. 56:2288–2298. 2007. View Article : Google Scholar : PubMed/NCBI
12	Monemdjou R, Vasheghani F, Fahmi H, Perez G, Blati M, Taniguchi N, Lotz M, St-Arnaud R, Pelletier JP, Martel-Pelletier J, et al: Association of cartilage-specific deletion of peroxisome proliferator-activated receptor γ with abnormal endochondral ossification and impaired cartilage growth and development in a murine model. Arthritis Rheum. 64:1551–1561. 2012. View Article : Google Scholar : PubMed/NCBI
13	Guan Y: Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol. 15:2801–2815. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dubois V, Eeckhoute J, Lefebvre P and Staels B: Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 127:1202–1214. 2017. View Article : Google Scholar : PubMed/NCBI
15	François M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K and Corvol MT: Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum. 54:1233–1245. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ and Aoyama T: PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol. 296:F328–F336. 2009. View Article : Google Scholar : PubMed/NCBI
17	Sha W, Thompson K, South J, Baron M and Leask A: Loss of PPARγ expression by fibroblasts enhances dermal wound closure. Fibrogenesis Tissue Repair. 5:52012. View Article : Google Scholar : PubMed/NCBI
18	Majdalawieh A and Ro HS: PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal. 8:e0042010. View Article : Google Scholar : PubMed/NCBI
19	Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, et al: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA. 100:15924–15929. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tyagi S, Gupta P, Saini AS, Kaushal C and Sharma S: The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2:236–240. 2011. View Article : Google Scholar : PubMed/NCBI
21	Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
22	Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, et al: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev. 58:726–741. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zoete V, Grosdidier A and Michielin O: Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta. 1771:915–925. 2007. View Article : Google Scholar : PubMed/NCBI
24	Guan Y and Breyer MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int. 60:14–30. 2001. View Article : Google Scholar : PubMed/NCBI
25	Michalik L and Wahli W: Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest. 116:598–606. 2006. View Article : Google Scholar : PubMed/NCBI
26	Bougarne N, Paumelle R, Caron S, Hennuyer N, Mansouri R, Gervois P, Staels B, Haegeman G and De Bosscher K: PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB. Proc Natl Acad Sci USA. 106:7397–7402. 2009. View Article : Google Scholar : PubMed/NCBI
27	Qi C, Zhu Y and Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 32:187–204. 2000. View Article : Google Scholar : PubMed/NCBI
28	Yu S and Reddy JK: Transcription coactivators for peroxisome proliferator-activated receptors. Biochim Biophys Acta. 1771:936–951. 2007. View Article : Google Scholar : PubMed/NCBI
29	Balakumar P, Rose M, Ganti SS, Krishan P and Singh M: PPAR dual agonists: Are they opening Pandora's Box? Pharmacol Res. 56:91–98. 2007. View Article : Google Scholar : PubMed/NCBI
30	Berger J and Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 53:409–435. 2002. View Article : Google Scholar : PubMed/NCBI
31	Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA and Coelho MM: Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. Eur J Pharmacol. 561:194–201. 2007. View Article : Google Scholar : PubMed/NCBI
32	Kytikova OY, Perelman JM, Novgorodtseva TP, Denisenko YK, Kolosov VP, Antonyuk MV and Gvozdenko TA: Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma. PPAR Res. 2020:89069682020. View Article : Google Scholar : PubMed/NCBI
33	Peraza MA, Burdick AD, Marin HE, Gonzalez FJ and Peters JM: The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci. 90:269–295. 2006. View Article : Google Scholar : PubMed/NCBI
34	Ammazzalorso A, De Filippis B, Giampietro L and Amoroso R: Blocking the peroxisome proliferator-activated receptor (PPAR): An overview. ChemMedChem. 8:1609–1616. 2013.PubMed/NCBI
35	Ferré P: The biology of peroxisome proliferator-activated receptors: Relationship with lipid metabolism and insulin sensitivity. Diabetes. 53 (Suppl 1):S43–S50. 2004. View Article : Google Scholar : PubMed/NCBI
36	Racke MK and Drew PD: PPARs in Neuroinflammation. PPAR Res. 2008:6383562008. View Article : Google Scholar : PubMed/NCBI
37	Terauchi Y and Kadowaki T: PPAR and diabetes. Nihon Rinsho. 63:623–629. 2005.(In Japanese). PubMed/NCBI
38	Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. J Mol Endocrinol. 27:1–9. 2001. View Article : Google Scholar : PubMed/NCBI
39	Gross B, Pawlak M, Lefebvre P and Staels B: PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 13:36–49. 2017. View Article : Google Scholar : PubMed/NCBI
40	Jones AB: Peroxisome proliferator-activated receptor (PPAR) modulators: Diabetes and beyond. Med Res Rev. 21:540–552. 2001. View Article : Google Scholar : PubMed/NCBI
41	Gurnell M, Savage DB, Chatterjee VK and O'Rahilly S: The metabolic syndrome: Peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 88:2412–2421. 2003. View Article : Google Scholar : PubMed/NCBI
42	Korbecki J, Bobiński R and Dutka M: Self-regulation of the inflammatory response by peroxisome proliferator-activated receptors. Inflamm Res. 68:443–458. 2019. View Article : Google Scholar : PubMed/NCBI
43	Hou Y, Moreau F and Chadee K: PPARγ is an E3 ligase that induces the degradation of NFκB/p65. Nat Commun. 3:13002012. View Article : Google Scholar : PubMed/NCBI
44	Scirpo R, Fiorotto R, Villani A, Amenduni M, Spirli C and Strazzabosco M: Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium. Hepatology. 62:1551–1562. 2015. View Article : Google Scholar : PubMed/NCBI
45	Wang S, Awad KS, Elinoff JM, Dougherty EJ, Ferreyra GA, Wang JY, Cai R, Sun J, Ptasinska A and Danner RL: G protein-coupled receptor 40 (GPR40) and peroxisome proliferator-activated receptor γ (PPARγ): An Integrated Two-Receptor Signaling Pathway. J Biol Chem. 290:19544–19557. 2015. View Article : Google Scholar : PubMed/NCBI
46	Badr MZ: PPAR research: Successful launching and promising future. PPAR Res. 2009:5435842009. View Article : Google Scholar : PubMed/NCBI
47	Colin C, Salamone S, Grillier-Vuissoz I, Boisbrun M, Kuntz S, Lecomte J, Chapleur Y and Flament S: New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines. Breast Cancer Res Treat. 124:101–110. 2010. View Article : Google Scholar : PubMed/NCBI
48	Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5:419–429. 2004. View Article : Google Scholar : PubMed/NCBI
49	Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodríguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, et al: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 425:90–93. 2003. View Article : Google Scholar : PubMed/NCBI
50	Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, et al: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol. 154:799–814. 2001. View Article : Google Scholar : PubMed/NCBI
51	Lee HY, Gao X, Barrasa MI, Li H, Elmes RR, Peters LL and Lodish HF: PPAR-α and glucocorticoid receptor synergize to promote erythroid progenitor self-renewal. Nature. 522:474–477. 2015. View Article : Google Scholar : PubMed/NCBI
52	Lee JM, Wagner M, Xiao R, Kim KH, Feng D, Lazar MA and Moore DD: Nutrient-sensing nuclear receptors coordinate autophagy. Nature. 516:112–115. 2014. View Article : Google Scholar : PubMed/NCBI
53	Blanco FJ, Rego I and Ruiz-Romero C: The role of mitochondria in osteoarthritis. Nat Rev Rheumatol. 7:161–169. 2011. View Article : Google Scholar : PubMed/NCBI
54	Gavriilidis C, Miwa S, von Zglinicki T, Taylor RW and Young DA: Mitochondrial dysfunction in osteoarthritis is associated with down-regulation of superoxide dismutase 2. Arthritis Rheum. 65:378–387. 2013. View Article : Google Scholar : PubMed/NCBI
55	Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, Verhaar JA, Somville J, De Clerck LS and Van Osch GJ: Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthritis Cartilage. 19:895–902. 2011. View Article : Google Scholar : PubMed/NCBI
56	Ratneswaran A, LeBlanc EA, Walser E, Welch I, Mort JS, Borradaile N and Beier F: Peroxisome proliferator-activated receptor δ promotes the progression of posttraumatic osteoarthritis in a mouse model. Arthritis Rheumatol. 67:454–464. 2015. View Article : Google Scholar : PubMed/NCBI
57	Vasheghani F, Monemdjou R, Fahmi H, Zhang Y, Perez G, Blati M, St-Arnaud R, Pelletier JP, Beier F, Martel-Pelletier J, et al: Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype. Am J Pathol. 182:1099–1106. 2013. View Article : Google Scholar : PubMed/NCBI
58	Vasheghani F, Zhang Y, Li YH, Blati M, Fahmi H, Lussier B, Roughley P, Lagares D, Endisha H, Saffar B, et al: PPARγ deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. Ann Rheum Dis. 74:569–578. 2015. View Article : Google Scholar : PubMed/NCBI
59	Wang Y, Zhao X, Lotz M, Terkeltaub R and Liu-Bryan R: Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α. Arthritis Rheumatol. 67:2141–2153. 2015. View Article : Google Scholar : PubMed/NCBI
60	Cordani N, Pisa V, Pozzi L, Sciorati C and Clementi E: Nitric oxide controls fat deposition in dystrophic skeletal muscle by regulating fibro-adipogenic precursor differentiation. Stem Cells. 32:874–885. 2014. View Article : Google Scholar : PubMed/NCBI
61	Reggio A, Spada F, Rosina M, Massacci G, Zuccotti A, Fuoco C, Gargioli C, Castagnoli L and Cesareni G: The immunosuppressant drug azathioprine restrains adipogenesis of muscle Fibro/Adipogenic Progenitors from dystrophic mice by affecting AKT signaling. Sci Rep. 9:43602019. View Article : Google Scholar : PubMed/NCBI
62	Cerquone Perpetuini A, Giuliani G, Reggio A, Cerretani M, Santoriello M, Stefanelli R, Palma A, Vumbaca S, Harper S, Castagnoli L, et al: Janus effect of glucocorticoids on differentiation of muscle fibro/adipogenic progenitors. Sci Rep. 10:53632020. View Article : Google Scholar : PubMed/NCBI
63	Reggio A, Rosina M, Palma A, Cerquone Perpetuini A, Petrilli LL, Gargioli C, Fuoco C, Micarelli E, Giuliani G, Cerretani M, et al: Adipogenesis of skeletal muscle fibro/adipogenic progenitors is affected by the WNT5a/GSK3/β-catenin axis. Cell Death Differ. 27:2921–2941. 2020. View Article : Google Scholar : PubMed/NCBI
64	Boileau C, Martel-Pelletier J, Fahmi H, Mineau F, Boily M and Pelletier JP: The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Arthritis Rheum. 56:2288–2298. 2007. View Article : Google Scholar : PubMed/NCBI
65	Fahmi H, Martel-Pelletier J, Pelletier JP and Kapoor M: Peroxisome proliferator-activated receptor gamma in osteoarthritis. Mod Rheumatol. 21:1–9. 2011. View Article : Google Scholar : PubMed/NCBI
66	Giaginis C, Giagini A and Theocharis S: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol Res. 60:160–169. 2009. View Article : Google Scholar : PubMed/NCBI
67	Hellio Le Graverand-Gastineau MP: OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed? Osteoarthritis Cartilage. 17:1393–1401. 2009. View Article : Google Scholar : PubMed/NCBI
68	Malemud CJ: Biologic basis of osteoarthritis: State of the evidence. Curr Opin Rheumatol. 27:289–294. 2015. View Article : Google Scholar : PubMed/NCBI
69	Kobayashi T, Notoya K, Naito T, Unno S, Nakamura A, Martel-Pelletier J and Pelletier JP: Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Arthritis Rheum. 52:479–487. 2005. View Article : Google Scholar : PubMed/NCBI
70	Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N and Fahmi H: Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is downregulated by interleukin-1beta in articular chondrocytes. Arthritis Res Ther. 9:R312007. View Article : Google Scholar : PubMed/NCBI
71	Qu Y, Zhou L and Wang C: Mangiferin inhibits IL-1β-induced inflammatory response by activating PPAR-γ in human osteoarthritis chondrocytes. Inflammation. 40:52–57. 2017. View Article : Google Scholar : PubMed/NCBI
72	Wang K, Han L, Zhu Y, Liu Y, Wang J and Xue C: Antarctic Krill Oil improves articular cartilage degeneration via activating chondrocyte autophagy and inhibiting apoptosis in osteoarthritis mice. J Funct Foods. 46:413–422. 2018. View Article : Google Scholar
73	Wang JS, Xiao WW, Zhong YS, Li XD, Du SX, Xie P, Zheng GZ and Han JM: Galectin-3 deficiency protects lipopolysaccharide-induced chondrocytes injury via regulation of TLR4 and PPAR-γ-mediated NF-κB signaling pathway. J Cell Biochem. 120:10195–10204. 2019. View Article : Google Scholar : PubMed/NCBI
74	Jingbo W, Aimin C, Qi W, Xin L and Huaining L: Betulinic acid inhibits IL-1β-induced inflammation by activating PPAR-γ in human osteoarthritis chondrocytes. Int Immunopharmacol. 29:687–692. 2015. View Article : Google Scholar : PubMed/NCBI
75	Kang X, Yang Z, Sheng J, Liu JB, Xie QY, Zheng W and Chen K: Oleanolic acid prevents cartilage degeneration in diabetic mice via PPARγ associated mitochondrial stabilization. Biochem Biophys Res Commun. 490:834–840. 2017. View Article : Google Scholar : PubMed/NCBI
76	Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, Guehring H, Christiansen C, Bay-Jensen AC and Kraus VB: Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: Lessons learned from failures and opportunities for the future. Osteoarthritis Cartilage. 24:2013–2021. 2016. View Article : Google Scholar : PubMed/NCBI
77	Vitale ND, Vandenbulcke F, Chisari E, Iacono F, Lovato L, Di Matteo B and Kon E: Innovative regenerative medicine in the management of knee OA: The role of Autologous Protein Solution. J Clin Orthop Trauma. 10:49–52. 2019. View Article : Google Scholar : PubMed/NCBI
78	Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S and Müller M: Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology. 148:2753–2763. 2007. View Article : Google Scholar : PubMed/NCBI
79	Zhou JL, Liu SQ, Qiu B, Hu QJ, Ming JH and Peng H: The protective effect of sodium hyaluronate on the cartilage of rabbit osteoarthritis by inhibiting peroxisome proliferator-activated receptor-gamma messenger RNA expression. Yonsei Med J. 50:832–837. 2009. View Article : Google Scholar : PubMed/NCBI